<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Supernus Pharmaceuticals, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XRÂŽ (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XRÂŽ (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Jack A. Khattar
    • FOUNDED
      2005
    • EMPLOYEES
      251-500
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    SCYNEXIS, Inc.

    SCYNEXIS, Inc.

    SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the li...

    SCYNEXIS, Inc. is a biotechnology company commi...

    Filing Type:    PU
    MedAnswers

    MedAnswers

    With 40 million infertile people worldwide, MedAnswers connects patients with mult...

    With 40 million infertile people worldwide, Med...

    Amount Raised:    $145,702.50
    Fundraising Status:    EC
    Filing Type:    CF
    NeuroMetrix, Inc.

    NeuroMetrix, Inc.

    Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...

    Founded in 1996 as a spinoff from the Harvard-M...

    Filing Type:    PU
    ESSA Pharma Inc.

    ESSA Pharma Inc.

    With a focus on the development of small molecule drugs for the treatment of cance...

    With a focus on the development of small molecu...

    Filing Type:    PU
    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    Relmada Therapeutics, Inc.

    Relmada Therapeutics, Inc.

    We are a clinical stage, publicly traded specialty pharmaceutical company, focused...

    We are a clinical stage, publicly traded specia...

    Filing Type:    PU
    VistaGen Therapeutics, Inc.

    VistaGen Therapeutics, Inc.

    VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...

    VistaGen Therapeutics (NASDAQ: VTGN) is a clini...

    Filing Type:    PU
    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...

    Axsome Therapeutics, Inc. is a clinical-stage b...

    Filing Type:    PU
    Auris Medical Holding Ltd.

    Auris Medical Holding Ltd.

    We at Auris Medical are dedicated to developing novel pharmaceutical products for ...

    We at Auris Medical are dedicated to developing...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.